๐๐๐ฉ๐ข๐ ๐๐ข๐ซ๐ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐จ๐ง ๐๐ข๐ง๐๐ฒ ๐๐ซ๐๐ฌ๐๐’๐ฌ ๐๐๐ฉ๐๐ซ๐ญ๐ฎ๐ซ๐ ๐๐ซ๐จ๐ฆ ๐ญ๐ก๐ ๐ ๐๐:
The recent departure of Vinay Prasad from the FDA, following controversy over Sarepta Therapeuticsโ gene therapy Elevidys, underscores the complex risks that family offices can face when making mission driven biopharma investments. Prasad, a vocal critic of accelerated approvals, left the FDA after spearheading a crackdown on Elevidys, prompted by three patie
Introducing Atelier Health (…and what we’ve been up to)
The global healthcare and life sciences sectors are at an inflection point, particularly in the rapidly evolving markets of the Middle East, India, and Southeast Asia.
๐๐ง๐ฅ๐จ๐๐ค๐ข๐ง๐ ๐๐ซ๐จ๐ฐ๐ญ๐ก: ๐๐ฎ๐ซ ๐๐ก๐๐ฌ๐ข๐ฌ ๐จ๐ง ๐ญ๐ก๐ ๐๐ข๐๐๐ฅ๐ ๐๐๐ฌ๐ญ, ๐๐ง๐๐ข๐ ๐๐ง๐ ๐๐ ๐๐ฌ๐ข๐ ๐๐ฌ ๐ฆ๐๐ฌ๐ฌ๐ข๐ฏ๐ ๐ ๐ซ๐จ๐ฐ๐ญ๐ก ๐จ๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ ๐ข๐ง ๐ก๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐ง๐ ๐ฅ๐ข๐๐ ๐ฌ๐๐ข๐๐ง๐๐๐ฌ
Risus quis varius quam quisque id diam vel quam elementum. Vulputate mi sit amet mauris commodo quis imperdiet.